Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX)

Geode Capital Management LLC trimmed its position in Immuneering Co. (NASDAQ:IMRX) by 5.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 209,641 shares of the company’s stock after selling 12,160 shares during the quarter. Geode Capital Management LLC owned 0.71% of Immuneering worth $522,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Corsair Capital Management L.P. bought a new position in Immuneering in the third quarter valued at about $25,000. Vontobel Holding Ltd. acquired a new position in shares of Immuneering in the third quarter valued at approximately $25,000. XTX Topco Ltd raised its holdings in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering during the 2nd quarter worth approximately $44,000. Finally, Tidemark LLC acquired a new stake in Immuneering during the 3rd quarter worth approximately $129,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price target on shares of Immuneering in a research note on Wednesday. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Immuneering in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.80.

Immuneering Stock Performance

IMRX stock opened at $2.07 on Friday. The stock’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $1.78. The company has a market cap of $64.27 million, a P/E ratio of -1.05 and a beta of -0.34. Immuneering Co. has a fifty-two week low of $1.00 and a fifty-two week high of $7.68.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.